Skip to main content

Table 1 Association between neogenin mRNA and protein levels and clinicopathological factors from breast cancer

From: Neogenin expression is inversely associated with breast cancer grade in ex vivo

Clinicopathological features Variable    P value
N (%) Expression of neogenin mRNA level mean ± SD
Age (years) ≥65 4 (7.4) 0.042 ± 0.035 0.060
  <65 50 (92.6) 0.270 ± 0.323  
Tumor size (cm) ≤2.00 24 (44.4) 0.298 ± 0.373 0.959
  2.01-5.00 26 (48.1) 0.217 ± 0.280  
  ≥5.00 4 (7.4) 0.372 ± 0.412  
Histology grade I 1 (1.9) 0.132 ± 0 0.032
  II 29 (53.7) 0.330 ± 0.343  
  III 24 (44.4) 0.192 ± 0.313  
Stage I 12 (22.2) 0.206 ± 0.319 0.818
  II 19 (35.2) 0.292 ± 0.322  
  III 14 (25.9) 0.254 ± 0.357  
  IV 9 (16.7) 0.302 ± 0.368  
Lymph node metastasis Yes 35 (64.8) 0.320 ± 0.356 0.16
  No 19 (35.2) 0.164 ± 0.257  
Vascular invasion Yes 38 (70.4) 0.272 ± 0.357 0.755
  No 16 (29.6) 0.247 ± 0.268  
Subtype Luminal A 13 (24.1) 0.407 ± 0.400 0.484
  Luminal B 14 (25.9) 0.217 ± 0.314  
  H type 14 (25.9) 0.199 ± 0.236  
  TNBC 13 (24.1) 0.244 ± 0.356  
ER + 27 (50) 0.309 ± 0.364 0.387
  - 27 (50) 0.221 ± 0.295  
PR + 21 (38.9) 0.279 ± 0.318 0.908
  - 33 (61.1) 0.256 ± 0.344  
HER2 + 21 (38.9) 0.239 ± 0.290 0.918
  - 33 (61.1) 0.281 ± 0.358  
Ki67 + 39 (72.2) 0.256 ± 0.333 0.128
  - 15 (27.8) 0.287 ± 0.335  
p53 + 21 (38.9) 0.308 ± 0.371 0.292
  - 33 (61.1) 0.237 ± 0.305  
  1. ER, estrogen receptor, HER-2, human epidermal growth factor-2; PR, progesterone receptor; TNBC, triple negative breast cancer.